APR 06, 2020 5:40 AM PDT

A New Lead in the Treatment of Hepatocellular Carcinomas

WRITTEN BY: Jasper Cantrell

Hepatocellular carcinoma, or HCC, is a type of liver cancer, and the third most prevalent cancer-caused death in the world. The lack of a certain set of driver oncogenes makes treatment and prognosis of HCC a challenge. A group from Shanghai targeted ACADL, long-chain acyl-Coa dehydrogenase, as a suitable lead for study, as it has been linked to HCC in other studies, saying “There is an urgent need for more complete understanding of the molecular mechanisms involved in deregulated HCC cell proliferation”. This study details why ACADL and another possible biomarker have promising futures in HCC treatment.

An examination of the HCC database in The Cancer Genome Atlas (TCGA) showed that in HCC tissues, levels of ACADL were far lower than in normal tissue. Levels even continued to decrease in HCC at later stages, making ACADL levels a possible biomarker for HCC progression. In vitro experiments, HCC cell lines deficient in ACADL expression, showed that re-expression of ACADL suppressed cellular proliferation. This did not affect HCC invasion into surrounding tissues, however. In vivo mouse experiments using the same cell lines confirmed the suppression of tumor growth in mice when ACADL was re-expressed.

To investigate why ACADL seemed to suppress HCC growth, the group began looking at other changes in expression levels in HCC cells versus normal cells. Of the possible hits, there were many members of the Hippo signaling pathway, which regulates cellular proliferation and apoptosis. YAP is a transcription factor linked to this pathway, and it seemed to be activated when ACADL levels were low and deactivated when ACADL levels were re-expressed in vitro. Artificial activation of YAP in ACADL re-expressing models reversed the anti-tumor effects, confirming the tumor suppression of ACADL is linked to YAP.

The group concludes “our data revealed a distinct decreased expression of ACADL in HBV-associated HCC and the low ACADL expression correlated with more aggressive clinical characteristics and poor prognosis”. The connection between low ACADL expression and YAP activation makes both attractive targets as biomarkers for cancer diagnostics. The tumor suppression effects seen when ACADL is re-expressed also points to a possible ACADL or YAP based therapy, although further study is needed. The group also concedes that the anti-cancer effects seen may be due to alterations in ROS control as both ACADL and YAP are connected to ROS generation or signaling. Regardless, this paper outlines the notion of ACADL and YAP as potential biomarker or treatment for HCC.

Sources: Nature, Targeted Oncology

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
NOV 11, 2020
Cell & Molecular Biology
Visualizing a Tumor Suppressor in Action
NOV 11, 2020
Visualizing a Tumor Suppressor in Action
Many types of cells in our bodies are short-lived and need to be replenished. Cell division has to be carefully controll ...
NOV 23, 2020
Cancer
Platelets May Protect Cancer Against PD-1 Therapies
NOV 23, 2020
Platelets May Protect Cancer Against PD-1 Therapies
One of cancer’s greatest tools is its ability to manipulate the immune system. Many cancer therapies have arisen t ...
NOV 23, 2020
Cancer
Where are the geographic hotspots of high mortality rates for women with colorectal cancer?
NOV 23, 2020
Where are the geographic hotspots of high mortality rates for women with colorectal cancer?
A study published in Clinical and Translational Gastroenterology highlights the risk disparities in death rates fro ...
DEC 07, 2020
Cancer
Black women with breast cancer have higher rates of mortality and comorbidities
DEC 07, 2020
Black women with breast cancer have higher rates of mortality and comorbidities
New research published today the American Cancer Society’s peer-reviewed journal, Cancer, looks at the mortality r ...
DEC 15, 2020
Cancer
New combination therapy may help patients with treatment resistance
DEC 15, 2020
New combination therapy may help patients with treatment resistance
New research from scientists at the UCLA Jonsson Comprehensive Cancer Center showcases a novel combination therapy that ...
JAN 20, 2021
Genetics & Genomics
Mutations in One Gene Can Lead to Cancer in Different Ways
JAN 20, 2021
Mutations in One Gene Can Lead to Cancer in Different Ways
Cancer and genetics are linked; for example, when a cell's genome accumulates mutations it can begin to divide uncon ...
Loading Comments...